Status:
UNKNOWN
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation
Lead Sponsor:
University Health Network, Toronto
Conditions:
Liver Transplantation
Hepatitis C
Eligibility:
All Genders
18-70 years
Brief Summary
The main objective of this study is to assess whether a recently-developed bioassay for the molecule "secreted fibrinogen-like protein 2" (sFGL2) can be used to predict the recurrence and/or progressi...
Detailed Description
Hepatitis C Virus infection (HCV) is a serious health problem worldwide, accounting for significant morbidity and mortality. The current treatment, combination therapy with pegylated IFNa/ribavirin re...
Eligibility Criteria
Inclusion
- For HCV positive subjects:
- Able and willing to give written informed consent
- Willing to follow the study protocol
- Diagnosis of chronic HCV infection based on two positive serology tests
- No history of active alcohol or drug abuse
- All six viral genotypes are considered
- Pre- and post transplant viral load data must be available
Exclusion
- Pregnancy
- HBV, HDV or HIV co-infection
- For Non-HCV subjects:
- Inclusion Criteria:
- Able and willing to give written informed consent
- Willing to follow the study protocol
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00701272
Start Date
June 1 2008
End Date
December 1 2014
Last Update
July 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toronto General Hospital (University Health Network)
Toronto, Ontario, Canada, M5G 2N2